Results demonstrated an increasing trend of dead cells and a concomitant decline in live cells following BTZ treatment, providing compelling evidence for BTZ’s cytotoxicity (Supplementary Fig. 1A).
← all excerpts
Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.
1
—
—